Experimental vaccine combo targets rare liver cancer in early trial
NCT ID NCT07430202
First seen Feb 26, 2026 · Last updated May 24, 2026 · Updated 16 times
Summary
This early-phase study tests a combination of a personalized vaccine (targeting a specific cancer protein) with three other drugs for people with advanced fibrolamellar liver cancer that has worsened despite prior treatment. The goal is to see if the combination is safe and can shrink tumors. About 27 participants aged 12 and older will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER (FIBROLAMELLAR HEPATOCELLULAR CANCER (FLC)) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins SKCCC
Baltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.